Heartland Bank & Trust Co Has $3.85 Million Position in AbbVie Inc. $ABBV
Heartland Bank & Trust Co significantly increased its stake in AbbVie Inc. by 82.2% during the third quarter, now holding 16,617 shares valued at $3.85 million. This makes AbbVie its 14th largest position, accounting for 1.6% of its total holdings. Other institutional investors also adjusted their positions in the pharmaceutical giant, with current institutional ownership at 70.23%.
Siligmueller & Norvid Wealth Advisors LLC Purchases Shares of 11,538 Abbott Laboratories $ABT
Siligmueller & Norvid Wealth Advisors LLC has acquired a new stake of 11,538 shares in Abbott Laboratories (NYSE:ABT) during Q3, valued at approximately $1.545 million. This news comes as Abbott Laboratories also announced its 409th consecutive quarterly dividend of $0.63 per share and recent analyst ratings suggest a "Moderate Buy" consensus for the stock with an average price target of $137.05. Additionally, insider Daniel J. Starks increased his holdings by purchasing 10,000 shares, bringing his total to over 6.7 million shares.
Raiffeisen Bank International AG Purchases 33,095 Shares of Abbott Laboratories $ABT
Raiffeisen Bank International AG increased its stake in Abbott Laboratories by 10.1% in the third quarter, acquiring 33,095 shares to boost its total holdings to 360,514 shares valued at approximately $47.99 million. This occurred as Abbott reported quarterly EPS of $1.50, matching estimates, but revenue of $11.46 billion, which was below expectations. The company also raised its quarterly dividend to $0.63 per share, resulting in an annualized dividend of $2.52 with a yield of roughly 2.2%.
China Universal Asset Management Co. Ltd. Sells 15,607 Shares of Abbott Laboratories $ABT
China Universal Asset Management Co. Ltd. significantly reduced its stake in Abbott Laboratories by 77.9% in Q3, selling 15,607 shares. Despite this, other institutional investors increased their positions, and an Abbott director purchased 10,000 shares. Abbott also raised its quarterly dividend and received a consensus "Moderate Buy" rating from analysts with an average price target of $137.05.
Rep. Thomas H. Kean, Jr. Purchases Shares of Abbott Laboratories (NYSE:ABT)
Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently purchased between $1,001 and $15,000 worth of Abbott Laboratories (NYSE: ABT) stock through his KEAN FAMILY PARTNERSHIP account. This comes as Abbott Laboratories reported meeting EPS estimates for the most recent quarter but missed on revenue, while simultaneously raising its quarterly dividend. Analysts currently rate ABT as a "Moderate Buy" with an average target price of $137.05.
Pay Less, Gain More: STE, RMD Top Abbott Laboratories Stock
This article suggests that investors might find better value and growth in STE and RMD stocks compared to Abbott Laboratories (ABT). It highlights that STE and RMD have lower valuations (P/OpInc) but higher revenue and operating income growth. The analysis uses financial metrics from both the present and one year prior to support the claim that ABT might be overvalued relative to its peers.
Exact Sciences shareholders approve merger with Abbott Laboratories
Exact Sciences Corp. shareholders have approved the proposed merger with Abbott Laboratories, making Exact Sciences a wholly-owned subsidiary of Abbott. The merger agreement passed with significant shareholder support, although the advisory vote on executive compensation was not approved. The completion of the merger is pending regulatory approvals and other customary closing conditions.
Exact Sciences Shareholders Approve Merger with Abbott Laboratories
Exact Sciences shareholders have approved the merger with Abbott Laboratories, under which Exact Sciences will become a wholly-owned subsidiary of Abbott. While the merger agreement and potential meeting adjournment were approved, shareholders voted against the proposed merger-related executive compensation. The transaction's completion is now contingent on fulfilling remaining regulatory and customary closing conditions.
ABBOTT LABORATORIES SEC 10-K Report
Abbott Laboratories has released its 2025 10-K report, detailing robust financial performance with net sales of $44.3 billion and significant growth in medical devices and established pharmaceutical products segments. The report highlights strategic initiatives such as key
Exact Sciences Stockholders Approve Acquisition by Abbott
Exact Sciences Corporation stockholders have approved the proposed acquisition by Abbott, with over 99% of votes cast in favor of the transaction. The acquisition is expected to close before the end of the second calendar quarter of 2026, granting Exact Sciences stockholders $105.00 in cash per share. Exact Sciences is a leading provider of cancer screening and diagnostic tests, including Cologuard® and Oncotype DX®.
Exact Sciences Stockholders Approve Acquisition by Abbott
Exact Sciences Corporation stockholders have approved the proposed acquisition by Abbott, with over 99% of votes cast in favor of the transaction. The acquisition is expected to close before the end of the second calendar quarter of 2026, with Exact Sciences stockholders receiving $105.00 in cash per share. Exact Sciences is a leading provider of cancer screening and diagnostic tests.
Abbott Laboratories (ABT) Announces Positive Results for Amulet 360 Left Atrial Appendage (LAA) Occlude
Abbott Laboratories announced positive clinical trial results for its Amulet 360 Left Atrial Appendage (LAA) occluder. The VERITAS Study showed top-tier performance for patients with paroxysmal and persistent AFib, with 93.9% achieving complete LAA closure after 45 days and a 99.8% implant success rate. Full results for this device are expected in 2027.
Thomas Kean Jr makes strategic moves in Abbott Laboratories and General Motors
Thomas Kean Jr, a representative for New Jersey’s 7th congressional district, recently made a new stock purchase of Abbott Laboratories (ABT) valued between $1,001 and $15,000, through the Kean Family Partnership. This move is notable as ABT is trading near its 52-week low and is considered undervalued by InvestingPro. Additionally, Kean Jr sold portions of his stakes in several companies, including General Motors (GM), Johnson & Johnson (JNJ), Markel Group Inc. (MKL), Microsoft Corporation (MSFT), and Stryker Corporation (SYK).
Abbott Laboratories (ABT) Maintains Quarterly Dividend
Abbott Laboratories (ABT) has announced it will maintain its quarterly dividend at $0.63 per share, reflecting a 2.26% forward yield and demonstrating a commitment to steady investor returns. The company shows strong financial health with a robust balance sheet, efficient operations, and valuation metrics suggesting potential undervaluation near historical lows. Despite sector-specific risks, its diversified revenue streams and global reach position it well for future stability and growth.
Abbott declares quarterly dividend of 63 cents per share
Abbott Laboratories has declared a quarterly dividend of 63 cents per share. This dividend is payable on May 15 to shareholders of record as of April 15. The announcement was made on February 20, 2026.
Abbott has paid a dividend every quarter since 1924
Abbott (NYSE: ABT) has declared its 409th consecutive quarterly dividend of $0.63 per share, payable on May 15, 2026. This extends the company's streak of increasing dividends for 54 consecutive years, maintaining its position in the S&P 500 Dividend Aristocrats Index. The healthcare leader has been paying quarterly dividends since 1924, demonstrating a consistent commitment to shareholder returns.
Abbott declares 409th consecutive quarterly dividend
Abbott has declared its 409th consecutive quarterly dividend of 63 cents per share, payable on May 15, 2026. The company has a strong history of dividend increases, raising its payout for 54 consecutive years and maintaining its status as an S&P 500 Dividend Aristocrat. Abbott, a global healthcare leader, attributes this consistent performance to its diverse portfolio across diagnostics, medical devices, nutritionals, and branded generic medicines.
Boston Scientific Stock is Down 20% This Year. Here Is What Investors Need to Know Before March 28
Boston Scientific (BSX) stock has declined significantly, trading near its 52-week low after a steep single-day drop due to Q4 EP sales missing estimates. Despite solid overall Q4 results, the market focused on perceived decelerations in key growth drivers, leading to analyst price target cuts. Investors are now looking to the CHAMPION trial readout on March 28 and the eventual Penumbra close as critical near-term catalysts that could reframe the company's growth story and potentially unlock significant upside from its currently undervalued price.
Regeneron Stock: Here’s Why Four Expected FDA Approvals Could Push its 36% Rally Even Higher
Regeneron Pharmaceuticals (REGN) is showing strong performance, nearing its 52-week high, driven by an anticipated four FDA approvals in 2026 and a robust pipeline. The company's recent BLA acceptance for garetosmab for FOP, with striking Phase 3 data, highlights its transition from a two-product company to a diversified late-stage platform. Analysts project continued revenue and EPS growth, with TIKR's valuation model suggesting significant upside, contingent on key pipeline readouts and approvals.
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
This article compares two MedTech companies, Boston Scientific (BSX) and Abbott (ABT), evaluating them as potential investments. It details each company's recent operational performance, strategic acquisitions, and financial metrics, including EPS estimates and price-to-sales ratios. While both are strong players in the MedTech sector with bullish analyst ratings, Abbott is presented as the more attractive option due to its current valuation and recent stock performance.
Woodley Farra Manion Portfolio Management Inc. Has $61.18 Million Stock Holdings in Abbott Laboratories $ABT
Woodley Farra Manion Portfolio Management Inc. significantly increased its stake in Abbott Laboratories (NYSE:ABT) by 14,530.7% in the third quarter, now holding 456,772 shares valued at $61.18 million. Other institutional investors also adjusted their positions in ABT, which continues to trade down slightly but has a strong institutional ownership of 75.18%. The company recently increased its quarterly dividend and analysts maintain a "Moderate Buy" rating with an average target price of $137.05.
Abbott Laboratories Stock Is Down 16% From Its 52-Week High. Here’s Where the Stock Could Go in 2026
Abbott Laboratories (ABT) shares are trading around $112, reflecting a 16% pullback from recent highs due to a FreeStyle Libre 3 sensor recall and weakness in the Nutrition segment. Despite these headwinds, the company's Medical Devices segment remains strong, and upcoming catalysts including the Exact Sciences acquisition and the Volt PFA launch have analysts projecting a mean price target of $133.39.
High-dose inhaled gas shows promise against tough lung infections
Beyond Air (NASDAQ: XAIR) has highlighted an independent review published in February 2026, which synthesizes data from 27 studies on high-dose inhaled nitric oxide (iNO) and its potential as a broad-spectrum antimicrobial therapy for respiratory infections. The review suggests that iNO, at concentrations well above the FDA-approved 20 ppm, exhibits multimodal antimicrobial activity against conditions like pneumonia, NTM, bronchiolitis, and COVID-19. Beyond Air believes this article will catalyze further research and accelerate the clinical development of high-dose iNO as a transformative treatment for pulmonary indications, despite potential regulatory hurdles and the early-phase nature of much of the evidence.
NewEdge Wealth LLC Has $6.20 Million Stake in Abbott Laboratories $ABT
NewEdge Wealth LLC increased its stake in Abbott Laboratories (NYSE:ABT) by 50.3%, bringing its total holding to 49,803 shares valued at approximately $6.20 million. This comes as institutional investors collectively own about 75.18% of the company's stock. Abbott Laboratories recently reported earnings in line with estimates and revenue slightly below consensus, while also raising its quarterly dividend to $0.63 per share.
SENS Eversense 365 Integrated With twiist Gains Full Availability
Senseonics Holdings, Inc. (SENS) announced the full availability of its Eversense 365 Continuous Glucose Monitoring (CGM) system, integrated with Sequel Med Tech’s twiist Automated Insulin Delivery (AID) system for U.S. type 1 diabetes patients. This integration is expected to boost customer adoption and sales for SENS, despite strong competition from larger players like Abbott and DexCom. The company also recently received CE Mark approval for Eversense 365 in Europe and reported strong preliminary Q4 2025 revenues, projecting significant growth for 2026.
Weight Management Supplements Market Report 2026: A $15+ Billion Market by 2030 Featuring Leading Players - Nestle, Abbott Laboratories, GSK, Glanbia, Herbalife Nutrition, and Amway - Forecast to 2035
The weight management supplements market is experiencing significant growth, projected to reach $15.08 billion by 2030 from $7.88 billion in 2026, driven by factors like increasing obesity rates, consumer focus on wellness, and personalized nutrition demand. Key trends include plant-based and botanical supplements, digital health integration, and online sales. Leading companies such as Nestle, Abbott, and Herbalife Nutrition are innovating with new products and strategic acquisitions to capitalize on market opportunities globally.
Weight Management Supplements Market Report 2026: A $15+ Billion Market by 2030 Featuring Leading Players - Nestle, Abbott Laboratories, GSK, Glanbia, Herbalife Nutrition, and Amway - Forecast to 2035
The weight management supplements market is experiencing significant growth, projected to reach $15.08 billion by 2030 from $6.69 billion in 2025, driven by rising obesity rates, increased consumer interest in wellness, and demand for personalized nutrition. Key growth factors include plant-based supplements, online sales, and innovations like GLP-1 nutrition companion offerings. Major players such as Nestle, Abbott Laboratories, and Herbalife Nutrition are contributing to this expansion through product development and strategic acquisitions, with North America leading and Asia-Pacific showing the fastest growth.
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up
Exact Sciences (EXAS) reported a net loss of 21 cents per share in Q4 2025, matching estimates, with revenues of $878.4 million beating the Zacks Consensus Estimate. Consolidated revenues for the full year reached $3.25 billion, an increase of 17.7%. The company saw strong revenue growth in both its Screening and Precision Oncology segments, though increased operating expenses led to a higher operating loss compared to the previous year.
ISRG's International Growth Outpaces US With 35% Procedure Volume
Intuitive Surgical (ISRG) is experiencing significant international growth, with procedures outside the US climbing 23% in 2025, outpacing its 15% domestic growth. This international expansion, driven by improved market access and training, now accounts for 35% of total global procedures. Other medtech companies like Medtronic and Abbott are also seeing international markets as key growth drivers, demonstrating a broader trend in the industry.
Boston Scientific’s $14.5B Penumbra Mega-Merger: A Strategic Reshaping of the Medtech Landscape
Boston Scientific (NYSE: BSX) is acquiring Penumbra, Inc. (NYSE: PEN) for $14.5 billion, a move that will reshape the medtech industry by positioning Boston Scientific as a dominant player in neurovascular and thrombectomy markets. This acquisition, structured as 73% cash and 27% stock, signals a strategic return to the neurovascular space for Boston Scientific and highlights a broader trend of consolidation and "Industrialization" within the medical technology sector. The deal is expected to create a duopoly with Stryker in the mechanical thrombectomy market, putting pressure on competitors like Medtronic.
Pharma Giants Amgen & Abbott Labs Commit to Transition Away from Horseshoe Crab Blood in Biomedical Testing Following Shareholder Engagement
Amgen Inc. and Abbott Laboratories have publicly committed to transitioning away from using horseshoe crab blood in biomedical testing, following shareholder engagements led by As You Sow. This decision aims to reduce supply chain vulnerabilities and protect declining horseshoe crab populations. The move is supported by the U.S. Pharmacopeia's recent approval of synthetic alternatives, removing major regulatory barriers and setting a precedent for other pharmaceutical manufacturers.
Hemenway Trust Co LLC Has $45.81 Million Holdings in Abbott Laboratories $ABT
Hemenway Trust Co LLC reduced its stake in Abbott Laboratories (NYSE:ABT) by 3.1% in the third quarter, bringing their total holdings to $45.81 million across 342,006 shares. Despite this reduction, Abbott Laboratories remains Hemenway's 7th largest holding, making up approximately 3.5% of their investment portfolio. The article also notes recent insider buying by Director Daniel J. Starks and provides an overview of other institutional investor activity, the company's financial performance, dividend increase, and current analyst ratings.
Sequel Med Tech and Senseonics Launch Transformative Combination of twiist and Eversense 365
Sequel Med Tech and Senseonics have announced the full U.S. availability of their integrated twiist Automated Insulin Delivery (AID) System with the Eversense 365 Continuous Glucose Monitoring (CGM) system. This combination offers a significant advancement for people with type 1 diabetes, providing the world's only one-year CGM integrated with an AID system, aiming to reduce the burden of frequent sensor changes and enhance diabetes management. Users of the twiist system also have the flexibility to choose between Eversense 365 or Abbott's FreeStyle Libre 3 Plus sensor.
Year-long glucose implant now links to insulin pump, easing life with type 1 diabetes
Senseonics (NASDAQ: SENS) and Sequel Med Tech announced the full U.S. availability of the twiist Automated Insulin Delivery (AID) system integrated with the Eversense 365 continuous glucose monitor (CGM). This combination offers people with type 1 diabetes a year-long CGM solution, reducing the need for frequent sensor changes and re-pairing while maintaining high accuracy. The twiist AID system is the first to be compatible with a year-long CGM, providing enhanced convenience and flexibility for long-term diabetes management.
United States Cancer Biomarker Market is Going to Boom | Merck KGaA • QIAGEN • Illumina • Myriad Genetics
Coherent Market Insights has released a comprehensive report on the United States Cancer Biomarker Market, forecasting its growth from 2026-2033. The report analyzes market trends, competition, geographic distribution, and identifies key players such as Roche, Thermo Fisher Scientific, and Illumina. It also outlines market segmentation for diagnostics, prognostics, therapeutics, and personalized medicine, providing insights for stakeholders.
ABT.SW Abbott Laboratories CHF100.00 pre-market 19 Feb 2026: Oversold bounce
ABT.SW Abbott Laboratories is showing an extreme oversold reading (RSI 4.70) pre-market on February 19, 2026, trading at CHF100.00, which often precedes a short-term bounce. Despite a premium valuation (PE 34.84), the company has strong cash metrics and solid liquidity. Traders are advised to wait for confirmation of a bounce, such as a volume-backed green candle or RSI recovery above 30.00, before targeting CHF106.00 and CHF109.55.
Our Bond's AI security platform has handled 1.4M requests
Our Bond, Inc. (formerly TG-17, Inc.) announced a corporate name change to align its brand with its consumer and enterprise presence as it expands globally. The company's AI-powered preventative personal security platform has handled over 1.4 million service requests, including more than 10,000 emergencies, with an investment exceeding $100 million. Despite positive operational news, the stock OBAI experienced negative market reactions, reflecting investor focus on financial strain.
Insulet (PODD) Shakes the Market with Q4 Earnings Beat as Omnipod 5 Dominance Continues
Insulet (PODD) reported a strong Q4 earnings beat, with an adjusted EPS of $1.55 against an estimate of $1.46, and revenue of $783.8 million, surpassing forecasts. This performance was driven by the successful adoption of its Omnipod 5 Automated Insulin Delivery system and its expansion into the Type 2 diabetes market. The company projects 20-22% constant currency revenue growth for the upcoming year, fueled by strategic international expansion, new sensor integrations, and upcoming algorithm updates for its Omnipod 5 system.
Medtronic plc Q3 FY2026 Earnings: Revenue Hits $9.0B With Highest Enterprise Growth in 10 Quarters
Medtronic plc reported stronger-than-expected Q3 FY2026 earnings, with non-GAAP EPS of $1.36 and revenue of $9.017 billion, marking the highest enterprise growth in 10 quarters. Despite beating analyst estimates for both revenue and EPS, Medtronic's shares fell approximately 3.2% as the company reiterated its full-year guidance rather than raising it. The company's Cardiovascular portfolio saw significant growth, particularly in Cardiac Ablation Solutions, although GAAP net income declined due to increased expenses.
DNA RNA Banking Services Market Is Going to Boom | Thermo Fisher Scientific • Illumina • 23andMe • AncestryDNA
This report by Coherent Market Insights analyzes the DNA RNA Banking Services Market, predicting substantial growth from 2026 to 2033 due to rising demand and innovation. It covers key market trends, drivers, competitive landscape, and strategic opportunities for industry leaders, identifying major players like Thermo Fisher Scientific and Illumina. The study utilizes analytical tools like SWOT analysis and Porter's Five Forces to provide comprehensive insights and forecasts for various segments and regions.
10 Health Care Stocks With Whale Alerts In Today's Session
This article highlights unusual options activity, known as "whale alerts," for ten health care stocks: AbbVie (ABBV), Abbott Laboratories (ABT), Amgen (AMGN), McKesson (MCK), Madrigal Pharmaceuticals (MDGL), Molina Healthcare (MOH), Merck & Co (MRK), Intellia Therapeutics (NTLA), UnitedHealth Group (UNH), and Vertex Pharmaceuticals (VRTX). It details specific call and put option trades, including strike prices, expiration dates, sentiment, and trade volumes, to help traders identify potential opportunities. The report explains key options terminology for better understanding of these alerts.
Danaher to buy Masimo for $9.9 billion
Danaher will acquire pulse oximeter maker Masimo in a $9.9 billion deal, aiming to strengthen its diagnostics portfolio. This acquisition marks Danaher's largest deal since 2023 and is expected to expand its presence in patient-monitoring products, complementing its existing medical devices. The deal is anticipated to close by the second half of 2026 and contribute to Danaher's adjusted diluted net earnings per share.
NEOS Investment Management LLC Acquires 72,502 Shares of Abbott Laboratories $ABT
NEOS Investment Management LLC increased its stake in Abbott Laboratories (NYSE:ABT) by 45.1% in the third quarter, acquiring an additional 72,502 shares and bringing its total holdings to 233,351 shares worth $31.26 million. Other hedge funds and institutional investors also adjusted their positions in ABT, which now sees 75.18% institutional ownership. Analysts have a "Moderate Buy" rating for Abbott Laboratories with an average target price of $137.05, and the company recently announced an increased quarterly dividend.
Merit Financial Group LLC Grows Holdings in Abbott Laboratories $ABT
Merit Financial Group LLC significantly increased its stake in Abbott Laboratories (NYSE:ABT) by 32.7% during the third quarter, bringing its total holdings to 81,263 shares valued at over $10.8 million. Other institutional investors have also adjusted their positions, and multiple Wall Street analysts have issued "buy" or "overweight" ratings for the stock, with a consensus target price of $137.05. Additionally, an insider, Director Daniel J. Starks, recently purchased 10,000 shares, and Abbott Laboratories announced an increased quarterly dividend.
Skandinaviska Enskilda Banken AB publ Buys 190,255 Shares of Abbott Laboratories $ABT
Skandinaviska Enskilda Banken AB publ significantly increased its stake in Abbott Laboratories by 51.6%, purchasing 190,255 shares to reach a total of 559,321 shares valued at approximately $74.9 million. This comes as Abbott Laboratories reported quarterly EPS in line with estimates but revenue slightly below expectations, while also increasing its quarterly dividend and seeing insider buying from director Daniel J. Starks. Analysts have a "Moderate Buy" rating on Abbott Laboratories with a consensus price target of $137.05, despite several recent price target reductions.
Medtronic (MDT): The Sleeping Giant Awakes with Strong Q3 FY26 Momentum
Medtronic (MDT) has transitioned from a stable but slow-moving company to a high-growth contender, driven by its revitalized cardiovascular portfolio and a successful "Medtronic Mindset" culture shift, as evidenced by its strong Q3 FY26 results. The company posted impressive organic revenue growth of 5.8% and expanded operating margins, while its robust product pipeline, including Pulsed Field Ablation and the Hugo RAS system, positions it to reclaim market share in key medical technology segments. Despite competitive and regulatory challenges, Medtronic's diversified portfolio, strong leadership, and focus on innovation provide a solid foundation for continued growth and an attractive dividend for investors.
Molecular Diagnostics Market is expected to reach US$ 37.19 billion by 2033 | Major key players - Hologic Inc, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, QIAGEN N.V
The global Molecular Diagnostics Market is projected to reach US$ 37.19 billion by 2033, growing at a CAGR of 5.8% from US$ 21.01 billion in 2024. Key market players include Hologic Inc, F. Hoffmann-La Roche Ltd, and Thermo Fisher Scientific Inc. Recent developments in the US and Japan highlight advancements in cancer detection, infectious disease testing, and personalized medicine, driven by new technologies and regulatory approvals.
A Look At Abbott Laboratories (ABT) Valuation As Libre 3 Lawsuit Raises Product Safety Concerns
Abbott Laboratories (ABT) is facing a wrongful death lawsuit concerning alleged defects in its FreeStyle Libre 3 glucose monitors, impacting investor perception of product safety risks. Despite recent share price declines related to these legal issues and other transient headwinds, a popular narrative suggests the stock is 15.5% undervalued with a fair value of $133.39, projecting future growth from new product launches and regulatory expansions. However, an alternative Discounted Cash Flow (DCF) analysis indicates the current share price of $112.68 is above its estimated value of $95.81, suggesting less room for error if growth or margins don't meet expectations.
Decent organic sales growth expected for Abbott Laboratories (ABT) in 2026
This article briefly states that Abbott Laboratories (ABT) is expected to show decent organic sales growth in 2026. No other details are provided.
Abbott class action claims glucose sensors sold with defect
A class action lawsuit has been filed against Abbott Diabetes Care Inc. and Abbott Laboratories, alleging that their FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose sensors are defective. Plaintiff Bijoy Shroff claims these sensors provide falsely low glucose readings and that Abbott knowingly sold them without disclosing this defect, only initiating a recall after numerous injuries and deaths were reported. The lawsuit seeks to represent a nationwide class of consumers, accusing Abbott of fraudulent omission, unjust enrichment, and violating consumer protection laws.
